- About Us
and three outstanding speakers:
NPD Case studies by Albumedix and Reach Separations
Dave Mead of Albumedix and Peter Ridgway of Reach Separations will talk about their individual approaches to New Product Development (NPD), the deciding factors in developing new products and services, the impact on strategic direction, and what the businesses have learnt through the process.
Each company has been on an exciting transformational journey, from starting up their businesses with a germ of an idea, to building and growing that business, and responding to changing market forces.
Medical Device Development by Datalink Electronics
Arash Ghadar of Datalink Electronics will talk about the key aspects of NPD from ideation to developing a commercially viable medical device.
Medical devices are an integral part of our lives, from home care, to primary care and hospitals. The journey of a medical device often starts from a healthcare insider identifying a problem that if solved, could lead to significant health and economic benefits.
This, however, is the start of a long journey, with every step requiring careful consideration and meticulous planning in order to ensure the outcome is fit for purpose and economically viable for all stakeholders.
The LATi 2018 LifeSciences Conference is a unique and focused networking event for people that work in the lifesciences, bioscience, pharma and drug discovery.
Xenogesis are the UK’s largest independent laboratory-based contract research organisation (CRO) specialising in preclinical drug metabolism and pharmacokinetics (DMPK), quantitative bioanalysis, in vitro pharmacology and expert interpretation.
Richard Weaver joined Astra Charnwood in 1997 within Discovery DMPK, Richard progressed to Group and Project Leader at AstraZeneca. During that time Richard gained and developed an in-depth knowledge of all aspects of In vitro and In vivo Drug Metabolism and Pharmacokinetics from Hit Identification to Candidate Drug nomination and beyond.
In 2011, Richard spotted an opportunity in the market and set up XenoGesis. His clear direction, vision and entrepreneurial approach to running a business has seen XenoGesis expand from 3 to 22 employees in just under five years, as well as now supporting over 100 companies and Universities around the world. His ambition is to build on this growth in the coming years whilst focusing on the XenoGesis reputation of providing a consultative approach to preclinical DMPK, TK and Bioanalysis projects to help clients achieve their drug discovery goals.
Albumedix, based in Nottingham, develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Its products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide.
Recombumin® is the world’s first and only supply of commercial recombinant human albumin, approved for use in the manufacture of human therapeutics. For example, Merck has used Albumedix’s products since 2006, to produce two vaccines that are used to treat millions of children worldwide against measles, mumps, rubella and Chicken pox; or the Albumedix Drug Delivery Technology used by CSL Behring to achieve 14 Day dosing for Haemophilia B therapy.
Dave Mead will talk about Albumedix’ journey over the last 30 years, from being part of a brewery to biopharmaceuticals. Covering how the company has developed extensive experience in the biopharmaceutical industry, with the necessary scientific, technical and regulatory expertise needed to produce recombinant products as well as supporting its partners in moving faster to market with superior biotherapeutics.
Reach Separations is the leading provider of contract purification across Europe. Focusing heavily upon the need to provide chromatography support around drug and agrochemical discovery Reach Separations has developed a substantial reputation in the field of enantiomeric purification and impurity isolation.
Since being founded in 2012 Reach Separations has developed a significant level of expertise in purification and is considered to a leading light in the field of Chiral chromatography and Supercritical Fluid Chromatography.
Peter Ridgway is a founding member and Business Development Director at Reach Separations where he helps to manage a portfolio of clients from Pharma and agrochemical sectors across Europe and the US. Before joining Reach Separations Peter spent 5 years working with Waters as their European Purification Manager working closely with clients using supercritical fluids. Prior to that he spent 10 years working as a Large Scale Chromatographer at AstraZeneca’s Process Research and Development facility in Loughborough.
Peter is an constant supporter of the art of chromatography and fulfills an active role on the board of The Chromatographic Society.
Datalink Electronics is an award winning ISO13485 accredited contract electronic design and manufacturing company, with a wealth of experience in a variety of industries in particular medical devices, scientific instrumentation, oil & gas, and rail. They provide a flexible and comprehensive service offering, including feasibility study, design, development, prototyping, certification support and full-scale production.
Arash Ghadar is a chartered engineer with substantial knowledge and expertise in developing commercial and industrial systems from medical devices to automotive industry. He is Datalink’s life sciences expert, acting as a consultant on the application of standards and regulations, ensuring that the products are developed to meet the users and regulatory requirements.
Arash has a PhD in optical biosensors from the University of Warwick, focusing on fluorescence-based immunoassays and analysis of biological interactions in the test sample. He also holds an MSc in control systems, specifically on artificial intelligence and emotive learning, as well as a BEng degree in electronics. Arash has a keen interest in connected healthcare, biosensors and artificial intelligence.
The LATi 2018 LifeSciences Conference and networking event attracts those working in BioScience, Pharmaceuticals, Drug Discovery, Heathcare, Medical Devices, Health Tech, and Life Sciences from around the region, and is open to anyone who works in these and related fields.
There will be plenty of opportunity to network and meet a wide range of companies involved in BioScience and Pharmaceutical research and development from across the region, with dedicated time allocated for networking and meeting exhibitors. Light refreshments will be available
The LATi Life Sciences Conference is free of charge to LATi community and LATi supporters, including MediCity, BioCity, Medilink community, Charnwood Campus, local Innovation Centres, and local universitities.